EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Rethinking anticholinergic burden in older adults: innovative approaches to detection and management

Geofrey Oteng Phutietsile, Prasad S Nishtala iD

Expert Review of Clinical Pharmacology · 03.08.2025 · 18 (8) · 551-562

DOI: 10.1080/17512433.2025.2546142 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 19.08.2025. Verfasst von Geofrey Oteng Phutietsile und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, University of Bath, Bath, UK. Hauptthemen laut MEDLINE: Cholinergic Antagonists, Cognitive Dysfunction. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Anticholinergic burden (AChB), the cumulative impact of medications with anticholinergic properties, is a modifiable risk factor linked to cognitive impairment, falls, and functional decline in older adults. Yet despite the availability of multiple AChB assessment tools, no consensus gold standard exists, and commonly used scales often rely on static, expert-derived drug rankings. AREAS COVERED: This narrative review synthesizes recent advances in AChB measurement and deprescribing. It critically evaluates established tools like the Anticholinergic Cognitive Burden (ACB) scale and Drug Burden Index (DBI), alongside emerging machine learning - based models such as the ML-AB scale. The review also explores the role of digital health innovations such as clinical decision support systems and wearable technologies in enhancing risk stratification and deprescribing interventions. EXPERT OPINION: While traditional tools remain useful, they suffer from limitations in adaptability and integration into routine workflows. Newer AI and data-driven approaches show promise in improving predictive accuracy and scalability. A paradigm shift is emerging, with future deprescribing efforts likely to depend on hybrid systems that combine mechanistic understanding with empirical robustness. For optimal impact, these tools must be validated, implemented thoughtfully, and aligned with patient-centered outcomes in diverse care settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholinergic AntagonistsCognitive DysfunctionHumansAgedMachine LearningRisk FactorsDeprescriptionsDecision Support Systems, ClinicalAccidental FallsRisk AssessmentWearable Electronic Devices

Stichwörter der Autor:innen

Anticholinergic burdenclinical decision supportcognitive declinedeprescribingdrug burden indexmachine learningolder adultspolypharmacy

Substanzen

Cholinergic Antagonists

Autor:innen und Institutionen

  • Department of Life Sciences, University of Bath, Bath, UK.
  • Centre for Therapeutic Innovation, University of Bath, Bath, UK.

ORCID-Profile: Prasad S Nishtala

Zitieren

APA

Phutietsile, G. O., & Nishtala, P. S. (2025). Rethinking anticholinergic burden in older adults: innovative approaches to detection and management. Expert Review of Clinical Pharmacology, 18(8), 551-562. https://doi.org/10.1080/17512433.2025.2546142

Vancouver

Phutietsile GO, Nishtala PS. Rethinking anticholinergic burden in older adults: innovative approaches to detection and management. Expert Review of Clinical Pharmacology. 2025;18(8):551-562. doi:10.1080/17512433.2025.2546142

BibTeX
@article{Phutietsile2025,
  author = {Phutietsile, Geofrey Oteng and Nishtala, Prasad S},
  title = {Rethinking anticholinergic burden in older adults: innovative approaches to detection and management},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2025},
  volume = {18},
  number = {8},
  pages = {551--562},
  doi = {10.1080/17512433.2025.2546142}
}
Kostenlos starten →